110 related articles for article (PubMed ID: 2245494)
1. Biochemical interactions between methotrexate and 1-beta-D-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study.
Newman EM; Villacorte DG; Testi AM; Krance RA; Harris MB; Ravindranath Y; Pinkel D
Cancer Chemother Pharmacol; 1990; 27(1):60-6. PubMed ID: 2245494
[TBL] [Abstract][Full Text] [Related]
2. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
3. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
[TBL] [Abstract][Full Text] [Related]
5. Effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells.
Roberts D; Peck C
Cancer Res; 1981 Feb; 41(2):505-10. PubMed ID: 7448798
[TBL] [Abstract][Full Text] [Related]
6. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
[TBL] [Abstract][Full Text] [Related]
8. Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1-beta-D-arabinofuranosyl cytosine in a human T-lymphoblastic cell line.
Verschuur AC; Van Gennip AH; Leen R; Voûte PA; Brinkman J; Van Kuilenburg AB
Int J Cancer; 2002 Apr; 98(4):616-23. PubMed ID: 11920624
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
11. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.
Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L
J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Ochs J; Rodman J; Abromowitch M; Kavanagh R; Harris M; Yalowich J; Rivera GK
J Clin Oncol; 1991 Jan; 9(1):139-44. PubMed ID: 1985163
[TBL] [Abstract][Full Text] [Related]
13. [Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)].
Matsuzaki A; Ishii E; Ueda K; Yanai F; Nibu K; Take H; Koga H; Miyazaki S; Inoue T; Miyake K
Rinsho Ketsueki; 1994 Sep; 35(9):862-70. PubMed ID: 7967055
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Higashigawa M; Hori H; Hirayama M; Kawasaki H; Ido M; Azuma E; Sakurai M
Leuk Res; 1997 Sep; 21(9):811-5. PubMed ID: 9393595
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro.
Akutsu M; Furukawa Y; Tsunoda S; Izumi T; Ohmine K; Kano Y
Leukemia; 2002 Sep; 16(9):1808-17. PubMed ID: 12200697
[TBL] [Abstract][Full Text] [Related]
16. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study.
Graham ML; Shuster JJ; Kamen BA; Land VJ; Borowitz MJ; Camitta B; Cheo DL; Harrison MP; Leventhal BG; Pinkel DP; Pullen DJ; Steuber P; Whitehead VM
Clin Cancer Res; 1996 Feb; 2(2):331-7. PubMed ID: 9816176
[TBL] [Abstract][Full Text] [Related]
17. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR
J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087
[TBL] [Abstract][Full Text] [Related]
18. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
19. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
[TBL] [Abstract][Full Text] [Related]
20. Sequential combination of methotrexate and 1-beta-D-arabinofuranosylcytosine shows synergistic effect on the generation of DNA strand breaks in a human promyelocytic leukemia cell line.
Tanizawa A; Kubota M; Takimoto T; Kito T; Akiyama Y; Kiriyama Y; Mikawa H
Adv Exp Med Biol; 1989; 253B():349-54. PubMed ID: 2610122
[No Abstract] [Full Text] [Related]
[Next] [New Search]